Our organs age at different rates, and a blood test determining how much they’ve each aged could predict the risk of conditions like lung cancer and heart disease decades later, finds a new study led by University College London (UCL) researchers.

ALS, or amyotrophic lateral sclerosis, can sometimes be difficult to diagnose or to predict how quickly the disease is likely to progress. A new study helps determine which blood tests are best at identifying and monitoring ALS. The study is published in the online issue of Neurology.

UCLA scientists have identified a potential new strategy for treating glioblastoma, the deadliest form of brain cancer, by reprogramming aggressive cancer cells into harmless ones.

When scientists stimulated cells to produce a protein that helps “water bears” survive extreme environments, the tissue showed much less DNA damage after radiation treatment.

ST. LOUIS, Feb. 25, 2025 /PRNewswire/ — MediBeacon Inc. today announced the National Medical Products Administration (NMPA) in China has approved the MediBeacon® TGFR Monitor and TGFR Sensor for the assessment of kidney function in patients with normal or impaired renal function. Lumitrace® (relmapirazin) injection, categorized as a drug in China, is under review and is targeted for approval in late 2025. The transdermal GFR technology includes Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together with the TGFR Monitor and TGFR Sensor allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body.

A novel scientific method developed at Tel Aviv University promises to accelerate our understanding of the gene PTEN, a key player in cellular growth. This breakthrough will help scientists better understand how cells grow and divide, potentially leading to advancements in the treatment of a range of conditions, including developmental disorders and various forms of cancer.

A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative for adults with sickle cell disease, according to results of a trial completed at Johns Hopkins and about 20 additional cancer centers nationwide and in London. The treatment, available at multiple U.S. medical centers, is a viable and less costly alternative to recently approved gene therapy products for sickle cell disease, the authors say.